Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | KDM4C | Q9H3R0 | 10/20 | 0.45 |
| ▸ | PARP1 | P09874 | 5/20 | 0.45 |
| ▸ | KDM5A | P29375 | 1/20 | 0.44 |
| ▸ | DAO | P14920 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.41 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19679334 | 0.86 | KDM4E (0.58) | KDM4EGAAKDM4CPARP1KDM5A | |
| SCHEMBL26018015 | 0.79 | PARP1 (0.45) | KDM4CPARP1KDM5ADAOMAPT | |
| SCHEMBL15775568 | 0.78 | PARP1 (0.49) | KDM4EGAAKDM4CPARP1 | |
| SCHEMBL24746791 | 0.76 | CDC7 (0.45) | KDM4EKDM4CPARP1KDM5ADAO | |
| SCHEMBL30064139 | 0.76 | CDC7 (0.45) | KDM4EKDM4CPARP1KDM5ADAO | |
| SCHEMBL10142469 | 0.75 | CDK4 (0.45) | KDM4EPDE3BPDE3ACSNK2A1 | |
| SCHEMBL29488099 | 0.73 | KDM4E (1.00) | KDM4EGAAPARP1MAPT | |
| SCHEMBL824574 | 0.73 | KDM4E (1.00) | KDM4EGAAPARP1MAPT | |
| SCHEMBL31691908 | 0.73 | DAO (0.53) | DAOMAPTPDE3BPDE3A | |
| SCHEMBL4805509 | 0.73 | DAO (0.53) | DAOMAPTPDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240182490-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2024-06-06 | — | — | US | disclosed |
| US-11884680-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| US-20220315601-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2022-10-06 | — | — | US | disclosed |
| US-10941160-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20200148703-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-05-14 | — | — | US | disclosed |
| US-10562915-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20180273547-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2018-09-27 | — | — | US | disclosed |
| US-10023592-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-20170158709-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2017-06-08 | — | — | US | disclosed |
| US-9598372-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20160115134-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2016-04-28 | — | — | US | disclosed |
| US-9115114-B2 | Bromodomain inhibitors | Quanticel Pharmaceuticals, Inc. (US) | 2015-08-25 | — | — | US | disclosed |
| US-20150183784-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2015-07-02 | — | — | US | disclosed |
| US-9034900-B2 | Bromodomain inhibitors | Quanticel Pharmaceuticals, Inc. (US) | 2015-05-19 | — | — | US | disclosed |
| US-20150111885-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2015-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170158709-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | KDM4E 137/4885GAA 2844/4885KDM4C 109/4885 |
| US-10562915-B2 | Bromodomain inhibitors | BRD3, EP300, BRPF3 | KDM4E 137/4885GAA 2844/4885KDM4C 109/4885 |
| US-20240182490-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | KDM4E 137/4885GAA 2844/4885KDM4C 109/4885 |
| US-20220315601-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | KDM4E 137/4885GAA 2844/4885KDM4C 109/4885 |
| US-20150111885-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | KDM4E 137/4885GAA 2844/4885KDM4C 109/4885 |
| US-10023592-B2 | Bromodomain inhibitors | BRD3, EP300, BRPF3 | KDM4E 137/4885GAA 2844/4885KDM4C 109/4885 |
| US-10941160-B2 | Bromodomain inhibitors | BRD3, EP300, BRPF3 | KDM4E 137/4885GAA 2844/4885KDM4C 109/4885 |
| US-20150183784-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | KDM4E 137/4885GAA 2844/4885KDM4C 109/4885 |
| US-20200148703-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | KDM4E 137/4885GAA 2844/4885KDM4C 109/4885 |
| US-11884680-B2 | Bromodomain inhibitors | BRD3, EP300, BRPF3 | KDM4E 137/4885GAA 2844/4885KDM4C 109/4885 |
| US-20180273547-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | KDM4E 137/4885GAA 2844/4885KDM4C 109/4885 |
| US-20160115134-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | KDM4E 137/4885GAA 2844/4885KDM4C 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.